Armetheon Product Pipeline

Tecarfarin is a novel reversible oral anticoagulant for patients with difficulty controlling anticoagulation or that cannot be treated with non-Vitamin K oral anticoagulants (NOACs).

Our novel antiarrhythmic compounds are designed to deliver a predictable dose response, rapid metabolic clearance, and improved safety profile over current therapies.

Espero owns the global IP rights to its compounds. Tecarfarin rights to China have been licensed to Lee’s Pharmaceutical (Hong Kong Exhange: 0950) who plans to initiate Phase 3 in China in 2019.